Related Experiment Videos
Neuron-specific gamma-enolase derived from human glioma
Neurochemical Pathology
|April 1, 1986
Summary
Neuron-specific gamma-enolase is elevated in some neurogenic tumors like gliomas. This protein may serve as a useful biomarker for monitoring glioma disease extent in patients.
Area of Science:
- Neuroscience
- Oncology
- Biochemistry
Background:
- Neuron-specific gamma-enolase (NSE) is a key glycolytic enzyme.
- NSE is typically found in neurons and neuroendocrine cells.
- Its presence in non-neuronal tumors warrants further investigation.
Purpose of the Study:
- To quantitatively assess neuron-specific gamma-enolase (NSE) levels in human neurogenic tumors.
- To evaluate NSE as a potential biomarker for gliomas.
- To correlate serum NSE levels with tumor burden.
Main Methods:
- Enzyme immunoassay (EIA) methods were developed for quantitative NSE analysis.
- Immunohistochemistry was used to localize NSE in tumor tissues and cell preparations.
- Serum NSE concentrations were measured in patients and transplanted mice.
Main Results:
- Significantly elevated NSE levels were detected in glioblastomas, astrocytomas, oligodendrogliomas, and medulloblastomas.
- Transplanted gliomas and cell lines showed lower NSE content compared to original tumors.
- Immunohistochemistry confirmed intense NSE staining in glioblastoma cells.
- Elevated serum NSE was observed in glioma patients and transplanted mice.
- Serum NSE levels in mice correlated with transplanted tumor size.
Conclusions:
- Neuron-specific gamma-enolase is produced in some neurogenic tumors of nonneuronal origin.
- Serum NSE shows potential as a biomarker for monitoring glioma disease extent.
- Further research can validate NSE's role in clinical glioma management.